NCT00379860终止1 期
A Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of LXR-623 Administered Orally to Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点开始时间: 2006年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 主要终点
- Safety is the primary outcome.
研究概览
简要总结
To evaluate the safety and tolerability of multiple doses of LXR in healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Generally healthy adults.
- •Liver function tests, triglycerideres, and creatinine must be below upper limit of normal at screening.
排除标准
- •A history or active presence of clinically important medical disease.
- •Any metal implants or devices.
- •Claustrophobia.
结局指标
主要结局
Safety is the primary outcome.
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Multi-Dose Safety and Pharmacokinetic Study of S-Equol in Healthy VolunteersHealthyNCT00998920Ausio Pharmaceuticals, LLC41
已完成
1 期
A Study in Rheumatoid ArthritisRheumatoid ArthritisNCT01253265Eli Lilly and Company32
终止
1 期
Study Evaluating Multiple Ascending Dose in Schizophrenia PatientsHealthyNCT00620568Wyeth is now a wholly owned subsidiary of Pfizer32
已完成
1 期
Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese MenHealthyNCT00385190Wyeth is now a wholly owned subsidiary of Pfizer24
已完成
1 期
A Study of Safety and Tolerability in Subjects With SchizophreniaSchizophreniaNCT01354353Denovo Biopharma LLC75